Skip to main content

RA Capital Management — Portfolio, Page 13

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
22
Industries
Biotechnology 20Health Care 12Therapeutics 11Medical 10Pharmaceutical 5Biopharma 5+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 289312 of 453
Biohaven Pharmaceutical
November 2025

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

Biotechnology · New Haven$200.0M Post Ipo Equity
Azalea Therapeutics
November 2025

Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.

Biotechnology · Berkeley$65.0M Series A
Seres Therapeutics
October 2025

Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.

Biopharma · Cambridge$3.6M Grant
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
Tango Therapeutics
October 2025

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$197.0M Post Ipo Equity
VitriVax
October 2025

VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.

Biotechnology · Boulder$17.3M Series B
Electra Therapeutics
October 2025

Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.

Biotechnology · San Francisco$183.0M Series C
LEXEO Therapeutics
October 2025

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Biotechnology · New York$154.0M Post Ipo Equity
Adcytherix
October 2025

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

Biotechnology · Marseille$122.8M Series A
Indapta Therapeutics
October 2025

Indapta Therapeutics is a privately held biotechnology company.

Biopharma · San Francisco$50.8M Series Unknown
TORL BioTherapeutics
October 2025

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Biopharma · Culver City$96.0M Series C
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Star Therapeutics
October 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Undisclosed
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Ansa Biotechnologies
October 2025

Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.

Biotechnology · Emeryville$46.4M Series B
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post Ipo Equity
ARS Pharmaceuticals
September 2025

ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.

Biopharma · San Diego$100.0M Post Ipo Debt
KalVista Pharmaceuticals
September 2025

KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).

Biotechnology · Cambridge$125.0M Post Ipo Debt
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post Ipo Equity
Metalex Commodities
September 2025

Metalex Commodities is a commodity trading company that specializes in the export of metal ores and concentrates.

Precious Metals · Houston$1.4M Grant
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post Ipo Equity
Celcuity
September 2025

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Biotechnology · Hamel$500.0M Post Ipo Debt
Mineralys Therapeutics
September 2025

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$287.5M Post Ipo Equity
Reframe Systems
August 2025

Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon

Construction · Andover$20.0M Series A

Where RA Capital Management invests

Biotechnology20
Health Care12
Therapeutics11
Medical10
Pharmaceutical5
Biopharma5

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 22 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Biohaven Pharmaceutical, Azalea Therapeutics, Seres Therapeutics, Hemab, Tango Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →